newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010

Outlook Therapeutics reiterates expected re-submission of BLA by September 2022 following receipt of additional correspondence from U.S. Food and Drug Administration (FDA) ISELIN, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc